Agilent and Visiopharm Co-promote Advanced Digital Precision Pathology Solutions
March 02 2020 - 11:00AM
Business Wire
Enabling better cancer diagnostics via artificial
intelligence-driven solutions
Agilent Technologies Inc. (NYSE: A)
and Visiopharm today announced that
they have entered a co-marketing agreement. The announcement is
happening at the USCAP 109th Annual
Meeting being held February 29 through March 5, 2020, in Los
Angeles, CA.
Based on a joint vision of end-to-end quality and
standardization of tissue diagnostics, the partnership will address
the currently unmet needs of pathology labs around the world. The
companies’ shared goal is to provide specific technologies,
products, and services that will improve the standardization of
pathology labs and accelerate accurate diagnoses.
Agilent and Visiopharm will co-market Visiopharm’s portfolio of
artificial intelligence-driven pathology solutions.
“This partnership is an exciting step in our shared commitment
in the fight against cancer,” said Simon Østergaard, Agilent vice
president and general manager of the company’s pathology group.
“Agilent’s market-leading portfolio of pathology staining
management solutions combined with Visiopharm’s digital
interpretation solutions will help facilitate improved patient care
and diagnostic accuracy. Together we will tackle some of the most
critical challenges faced by pathology labs and pave the way toward
the fully digitalized lab of the future.”
“The transformation into next-generation precision pathology is
important to realize the full potential of tissue pathology in this
dawning era of personalized medicine,” said Michael Grunkin, CEO of
Visiopharm. “This transformation requires a holistic approach to
standardization along the entire diagnostic journey from biopsy to
diagnosis. We are excited to be working with Agilent on precisely
that. With their complementary product portfolio and longstanding
legacy of innovation and quality in this field, we see a very
strong match.”
The co-marketing relationship will result in offerings that will
improve the standardization of pathology labs and accelerate
accurate diagnoses for their patients. Digital pathology is the
future, although many labs have waited to adopt it due to the lack
of choices currently available and the expense of adoption. This
effort will enable labs to gradually adopt digital technologies in
a flexible and scalable manner.
About Visiopharm A/S
Visiopharm® is a world leader in AI-driven digital precision
pathology software. Leading biopharmaceutical companies, contract
research organizations (CRO), academic medical centres, and
diagnostic pathology labs all over the world use Visiopharm’s
technology for tissue-based research and diagnostics. Its solutions
use the latest advancements in artificial intelligence and deep
learning to make the most comprehensive, highly configurable, and
accurate tissue mining tools available on the market today.
Visiopharm was founded in 2001 and is privately owned. The company
operates internationally with over 900 licenses in more than 38
countries. Company headquarters are in Denmark’s Medicon Valley,
with further offices in London, England, Munich, Germany, and
Westminster, Colorado. Follow Visiopharm on LinkedIn and Twitter.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life
sciences, diagnostics, and applied chemical markets. Now in its
20th year as an independent company delivering insight and
innovation toward improving the quality of life, Agilent
instruments, software, services, solutions, and people provide
trusted answers to customers' most challenging questions. The
company generated revenue of $5.16 billion in fiscal 2019 and
employs 16,300 people worldwide. Information about Agilent is
available at www.agilent.com. To
receive the latest Agilent news, subscribe to the Agilent
Newsroom. Follow Agilent on
LinkedIn, Twitter, and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200302005288/en/
Naomi Goumillout Agilent Technologies +1 781 266 2819
naomi.goumillout@agilent.com
Adrian Arechiga Visiopharm +45 88 20 20 88 aar@visiopharm.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Feb 2024 to Mar 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Mar 2023 to Mar 2024